Spindle assembly checkpoint and p53 deficiencies cooperate for tumorigenesis in mice

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1483-1489

  Chi, Ya Hui ^a   Ward, Jerrold M ^b   Lily, I Cheng ^b   Junichiro, Yasunaga ^a   Jeang, Kuan The ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Room 306 ^*  (United States)

Author keywords

Mad2; Madl; P53; Spindle assembly checkpoint; Tumorigenesis

Indexed keywords

PROTEIN MAD1; PROTEIN MAD2; PROTEIN P53; BUB1 SPINDLE CHECKPOINT PROTEIN; CELL CYCLE PROTEIN; MAD2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CARCINOGENICITY; CELL FUNCTION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME SEGREGATION; CONTROLLED STUDY; GENE FUNCTION; GENOTYPE; KNOCKOUT MOUSE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SPINDLE ASSEMBLY CHECKPOINT; TUMOR VOLUME; ANIMAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CROSS BREEDING; FEMALE; GENE FREQUENCY; GENETICS; LITTER SIZE; MISSENSE MUTATION; MITOSIS SPINDLE; MOUSE MUTANT; NEOPLASM; PATHOLOGY;

ANIMALS; CELL CYCLE PROTEINS; CROSSES, GENETIC; FEMALE; G1 PHASE; GENE FREQUENCY; GENOTYPE; LITTER SIZE; MICE; MICE, KNOCKOUT; MITOTIC SPINDLE APPARATUS; MUTATION, MISSENSE; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60549094835     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24094     Document Type: Article

References (46)

1. Golias CH, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract 2004:58:1134-41.
2. Massague J. Gl cell-cycle control and cancer. Nature 2004;432:298-306.
3. Chi YH, Jeang KT. Aneuploidy and cancer. J Cell Biochem 2007;102:531-8,
4. Gagos S, Irminger-Finger I. Chromosome instability in neoplasia: chaotic roots to continuous growth. Int J Biochem Cell Biol 2005;37:1014-33.
5. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004;432:338-41.
6. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695-701.
7. Thurberg BL, Duray PH, Odze RD. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. Hum Pathol 1999;30:745-52.
8. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006;18:658-67.
9. Breivik J. The evolutionary origin of genetic instability in cancer development. Semin Cancer Biol 2005;15:51-60.
10. Gollin SM. Mechanisms leading to chromosomal instability. Semin Cancer Biol 2005;15:33-42.
11. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
12. Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 2003:112: 407-21.
13. Kolodner RD, Putnam CD, Myung K. Maintenance of genome stability in Saccharomyc.es cerevisiae. Science 2002;297:552-7.
14. Spencer F, Gerring SL, Connelly C, Hieter P. Mitotic chromosome transmission fidelity mutants in Saccharomyces cerevisiae. Genetics 1990:124:237-49.
15. Yuen KW, Montpetit B, Hieter P. The kinetochore and cancer: what's the connection? Curr Opin Cell Biol 2005;17:576-82.
16. Baker DJ, Chen J, van Deursen JM. The mitotic checkpoint in cancer and aging: what have mice taught us? Curr Opin Cell Biol 2005;17:583-9.
17. Yuen KW, Montpetit B. Hieter P. The kinetochore and cancer: what's the connection? Curr Opin Cell Biol 2005;17:576-82.
18. Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D, Kidd A, Mehes K, Nash R, Robin N, Shannon N, Tolmie J, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB IB. Nat Genet 2004:36: 1159-61.
19. Matsuura S, Matsumoto Y, Morishima K, Izumi H, Matsumoto H, Ito E, Tsutsui K, Kobayashi J, Tauchi H, Kajiwara Y, Hama S, Kurisu K, et al. Monoallelic BUB IB mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A 2006:140:358-67.
20. Coe BP, Lee EH, Chi B, Girard L. Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosomes Cancer 2006:45:11-19.
21. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Taka-hashi T. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes. hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999:18:4295-300.
22. Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S, Mahmood R, Yang YM, Xu M, Rao CV. Slippage of mitotic arrest and enhanced tumor development in mice with BubRl haploinsufficiency. Cancer Res 2004:64:440-5.
23. Twanaga Y, Chi YH, Miyazato A, Sheleg S, Haller K, Peloponese JM, Jr, Li Y, Ward JM, Benezra R, Jeang KT. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res 2007;67:160-6.
24. Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev 2000;14:2277-82.
25. Michel LS, Liberal V, Chatterjee A. KirchweggerR, Pasche B. Gerald W, Dobles M, Sorger PK, Murty VV, Benezra R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001 ;409:355-9.
26. Wang Q, Liu T, Fang Y, Xie S, Huang X, Mahmood R, Ramaswamv G, Sakamoto KM, Darzynkiewicz Z,Xu M, Dai W. BUBR1 deficiency results in abnormal megakarvopoiesis. Blood 2004; 103:1278-85.
27. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007:11:25-36.
28. Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM. Rael is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003;160:341-53.
29. Kalitsis P, Fowler KJ, Griffiths B, Earle E, Chow CW, Jamsen K, Choo KH. Increased chromosome instability but not cancer predisposition in haploinsnfficient Bub3 mice. Genes Chromosomes Cancer 2005:44:29-36.
30. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834-42.
31. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
32. Burds AA, Lutum AS, Sorger PK. Generating chromosome instability through the simultaneous deletion of Mad2 and p53. Proc Natl Acad Sci USA 2005:102:11296-301.
33. Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MS, Cogen PH. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci USA 1991;88:7825-9.
34. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6094-7.
35. Volkers N. Of pedigrees, probes, and p53: 20 years of family studies. J Natl Cancer Inst 1991 ;83:1707-9.
36. Zambetti GP. The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 2007;213:370-3.
37. Blackburn AC, McLary SC, Naeem R, Luszcz J, Stockton DW, Done- hower LA, Mohammed M, Mailhes JB, Soferr T, Naber SP, Otis CN, Jerry DJ. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res 2004;64:5140-7.
38. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA, Ir, Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995;14:16-22.
39. Houghtaling S, Granville L, Akkari Y, Torimaru Y, Olson S, Finegold M, Grompe M. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res 2005:65:85-91.
40. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000; 101:635-45.
41. Margolis RL, Lohez OD, Andreassen PR. Gl tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003;88:673-83.
42. Baek KH, Shin HJ, Yoo JK, Cho JH, Choi YH, Sung YC, McKeon F, Lee CW. p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. J Leukoc Biol 2003;73:850-61.
43. Chung E, Chen RH. Spindle checkpoint requires Madl-bound and Madl-free Mad2. Mol Biol Cell 2002;13:1501-11.
44. Kallio M, Weinstein J, Daum JR, Burke DJ, Gorbsky GJ. Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-proraoting complex, and is involved in regulating anaphase onset and late mitotic events. J Cell Biol 1998;141:1393-406.
45. Mapelli M, Massimiliano L, Santaguida S, Musacchio A. The Mad2 conformational dimer: structure and implications for the spindle assembly checkpoint. Cell 2007; 131:730-43.
46. Meraldi P, Draviam VM, Sorger PK. Timing and checkpoints in the regulation of mitotic progression. Dev Cell 2004:7:45-60.